Wegovy Pill (oral semaglutide 25 mg)vsHenry Meds Compounded Oral Semaglutide (Dissolvable Tablets / Drops)

Semaglutide is a GLP-1 receptor agonist. It mimics the gut hormone GLP-1 to boost glucose-dependent insulin release, slow how fast the stomach empties, and signal fullness in the brain, which together reduce appetite and calorie intake. The oral formulation uses an absorption enhancer (SNAC) to get the peptide across the stomach lining, which is why empty-stomach dosing matters.

The active ingredient is semaglutide, the same GLP-1 receptor agonist found in branded products, prepared by a compounding pharmacy as a dissolvable tablet or sublingual drop. The intent is absorption through the tissues of the mouth to bypass the digestive breakdown that limits swallowed peptide pills, though real-world absorption from these routes is reported to be low and variable.

In the phase 3 OASIS 4 trial (NEJM, 2025; n=307 adults with overweight/obesity, without diabetes), oral semaglutide 25 mg produced an estimated mean weight change of -13.6% at week 64 versus -2.2% for placebo, with about 30% of the drug group losing at least 20% of body weight. Novo reports up to ~16.6% mean loss with full adherence, on par with injectable Wegovy 2.4 mg.

Semaglutide as a drug class has strong efficacy data, but there are no large-scale outcomes trials for compounded sublingual or oral-troche formulations specifically, and reported bioavailability of sublingual routes is only about 3-10%. Expected weight loss is therefore less predictable than with FDA-approved oral semaglutide; results depend heavily on the formulation, dose actually absorbed, and adherence.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation, typically worst during dose escalation and easing over time. Rare but serious risks include pancreatitis and gallbladder problems; it carries a boxed warning for thyroid C-cell tumors based on animal data. Discuss your history with a licensed provider.

Expect the usual GLP-1 GI effects: nausea, diarrhea, vomiting, and constipation, often worst early on. An added concern with compounded products is potential variability in potency and purity, since these are not FDA-reviewed. Rare serious risks like pancreatitis exist across the class. Discuss your full history with a licensed provider and report problems promptly.

As of May 2026, self-pay pricing starts around $149/month for the 1.5 mg starter and 4 mg doses, with 4 mg rising to $199/month after April 15, 2026 and higher maintenance doses around $299/month. Commercially insured patients with coverage may pay as little as $25/month with the savings offer. Confirm current pricing at NovoCare or your pharmacy.

As of May 2026, reported all-inclusive pricing for Henry's oral/sublingual semaglutide ranges roughly $149-$249/month (covering medication, provider visits, supplies, and shipping), with higher doses adding about $100/month. It is cash-pay only with no insurance accepted. Pricing varies by source and changes over time, so confirm directly with Henry Meds.

Intended for adults with obesity (BMI >=30) or overweight (BMI >=27) with at least one weight-related condition, used with diet and exercise. Not for people with a personal or family history of medullary thyroid carcinoma or MEN2, and prescribers screen for pancreatitis history and other GLP-1 contraindications.

Adults seeking weight management who qualify after a telehealth evaluation and who are comfortable with a compounded (non-FDA-approved) medication. Standard GLP-1 contraindications apply, including personal or family history of medullary thyroid carcinoma or MEN2 and a history of pancreatitis. A prescription is still required.